- 719
- 117 009
GU Oncology Now
United States
เข้าร่วมเมื่อ 5 ส.ค. 2022
GU Oncology Now delivers the latest news in therapeutics, clinical trials, conference coverage, and more, highlighting important advancements in genitourinary oncology treatments and technologies with the goal of better informing oncology decisions and improving patient outcomes.
BOND-003 With Dr. Mark D. Tyson: Cretostimogene for BCG-Unresponsive Bladder Cancer
Mark D. Tyson, MD, of Mayo Clinic, discusses the data from cohort P of the BOND-003 trial, exploring the potential of cretostimogene grenadenorepvec in treating papillary-only BCG-unresponsive, non-muscle-invasive bladder cancer. He explains the trial’s focus on providing the urologic oncology community with data for informed treatment decisions, the unique mechanism of action exploiting RB pathway deficiencies, and the broader implications for bladder cancer care. Dr. Tyson also sheds light on FDA guidance that spurred innovation in this field and the critical importance of trials aimed at preserving bladder function in high-risk patients.
มุมมอง: 4
วีดีโอ
Overcoming the BCG Shortage With TARA-002 for High-Grade NMIBC
มุมมอง 682 ชั่วโมงที่ผ่านมา
Neal Shore, MD, FACS, Carolina Urologic Research Center, gives an overview of the investigational drug TARA-002 for high-grade non-muscle invasive bladder cancer and how the treatment can potentially aid patients during the ongoing BCG shortage. He elaborates on how TARA-002 differs from existing therapies, and how it might influence the treatment landscape for both BCG-naive and BCG-unresponsi...
The ABLE-32 Study: Nadofaragene Firadenovec for Intermediate-Risk NMIBC
มุมมอง 232 ชั่วโมงที่ผ่านมา
Neal Shore, MD, FACS, Carolina Urologic Research Center, discusses the ABLE-32 study on the use of nadofaragene firadenovec for intermediate-risk, BCG-unresponsive non-muscle invasive bladder cancer. He reviews the history of the treatment in high-risk disease, and the anticipated outcomes of ABLE-32. (0:12) Nadofaragene for High-Risk Disease, Data of FDA Approval (2:38) Differences of IR and H...
The Phase 3 CLARIFY Trial With 64Cu-SAR-bisPSMA: A Next-Generation PSMA Imaging Agent
มุมมอง 562 ชั่วโมงที่ผ่านมา
David Morris, MD, FACS, of Urology Associates of Nashville, discusses the emerging role of copper-based PSMA imaging agents, specifically Clarity Pharmaceuticals' 64Cu-SAR-bisPSMA, in prostate cancer diagnostics. He highlights the unique dual-binding structure of this tracer, which may offer increased sensitivity and specificity compared to gallium-based PSMA tracers. The conversation explores ...
AI-Powered Biomarkers and Precision Medicine in High-Risk NMIBC
มุมมอง 419 ชั่วโมงที่ผ่านมา
Amanda Nizam, MD, of Cleveland Clinic, speaks with Vignesh Packiam, MD, of Rutgers Cancer Institute, about his innovative study on an AI-powered model designed to predict patient response to intravesical BCG in high-risk non-muscle invasive bladder cancer. They discuss the study's rationale, findings, and implications for precision medicine, highlighting how AI evaluates histopathologic feature...
CheckMate 67T: Logistical Benefits, Considerations of Subcutaneous Nivolumab for RCC
มุมมอง 56วันที่ผ่านมา
Laurence Albiges, MD, PhD, of Gustave Roussy, expands on the findings from CheckMate 67T, which examines subcutaneous (subQ) administration of nivolumab for renal cell carcinoma. Dr. Albiges highlights the logistical advantages of subQ nivolumab, including reduced chair time and improved patient convenience, while addressing the challenges of integrating this modality into real-world practice. ...
Subcutaneous Nivolumab for RCC: CheckMate 67T Practice-Changing Results
มุมมอง 5114 วันที่ผ่านมา
Laurence Albiges, MD, PhD, of Gustave Roussy, provides an overview of the CheckMate 67T trial, a phase 3 study evaluating the safety and efficacy of subcutaneous (subQ) administration of nivolumab compared to intravenous administration in patients with renal cell carcinoma. Dr. Albiges highlights the study's key findings, including its success in meeting co-primary endpoints of pharmacokinetic ...
Urology on the Beach 2025 Preview: New Trends in RCC Care and Imaging
มุมมอง 9714 วันที่ผ่านมา
Brian Shuch, MD, of UCLA Health, previews his upcoming sessions at Urology on the Beach 2025, taking place January 17, 2025, to January 19, 2025, at the Fontainebleau Miami Beach. This comprehensive event covers all aspects of urology with presentations from leading experts in the field. Dr. Shuch's presentation will cover the use of molecular imaging agents and their role in risk stratificatio...
Molecular Imaging Breakthroughs in Kidney Cancer: Dr. Brian Shuch at SUO 2024
มุมมอง 8914 วันที่ผ่านมา
Brian Shuch, MD, of UCLA Health, shares the key takeaways from his SUO 2024 presentation on advancements in molecular imaging and theranostics for kidney cancer. Dr. Shuch highlights the potential of cutting-edge technologies, like CA9-based imaging and zirconium-labeled girentuximab, in improving diagnostic accuracy and treatment planning. He also discusses how these developments mirror succes...
SunRISe-1 Data: Promising Complete Response Rate, Durable Outcomes With TAR-200 for NMIBC
มุมมอง 7821 วันที่ผ่านมา
Sia Daneshmand, MD, discusses the groundbreaking findings from the SunRISe-1 study, highlighting TAR-200’s impressive complete response rates as a monotherapy for BCG-unresponsive, high-risk non-muscle-invasive bladder cancer. Dr. Daneshmand describes how TAR-200’s sustained drug delivery sets it apart from conventional intravesical therapies, offering a promising new approach to bladder-sparin...
PENELOPE: TAR-200 Shows Deeper Tissue Penetration vs Standard Intravesical Therapy
มุมมอง 17621 วันที่ผ่านมา
Sia Daneshmand, MD, discusses the key findings from the PENELOPE study he presented at the SUO 2024 Annual Meeting, which evaluated the tissue penetration of gemcitabine metabolites delivered via the TAR-200 device compared to standard intravesical installation. He explains how TAR-200 achieves sustained drug release for up to 96 hours, delivering active metabolites into deeper bladder tissue l...
Looking Ahead: TAR-200's Evolving Role in NMIBC and Future Directions in Bladder Cancer Care
มุมมอง 9021 วันที่ผ่านมา
Christopher Cutie, MD, of Johnson & Johnson Innovative Medicine, shares his thoughts on the potential of TAR-200 to redefine care for BCG-unresponsive, high-risk non-muscle-invasive bladder cancer (NMIBC). Designed as a bladder-preserving alternative for patients unfit or unwilling to undergo radical cystectomy, TAR-200 integrates seamlessly into urologic practices, offering logistical advantag...
The SunRISe Trials and TAR-200: Bladder-Sparing Therapies for NMIBC
มุมมอง 14121 วันที่ผ่านมา
Christopher Cutie, MD, of Johnson & Johnson Innovative Medicine, describes the innovative TAR-200 system and its role in providing sustained intravesical drug delivery of gemcitabine to improve outcomes and preserve patients' bladders. Dr. Cutie explains how advancements like the TAR-200 system, offering 24/7 localized therapy, are redefining standards for patient care. Dr. Cutie also highlight...
Frontline vs Sequenced Therapies in BCG-Unresponsive Bladder Cancer: What's the Best Approach?
มุมมอง 10221 วันที่ผ่านมา
In the fifth segment of this NMIBC roundtable, the panelists discuss the evolving landscape of bladder cancer treatments, focusing on balancing bladder-sparing therapies and timely radical cystectomy. The group explores the sequencing of emerging agents, the impact of treatment lines on efficacy, and practical considerations for patient counseling. #bladdercancer #oncology #cancer #cancerresear...
Combination Therapies in Bladder Cancer: Insights and Challenges
มุมมอง 4821 วันที่ผ่านมา
In part four of this roundtable, Roger Li, MD, Vitaly Margulis, MD, Kyle Rose, MD, and Paul Crispen, MD, debate the potential of combining intravesical immunotherapy with immune checkpoint inhibitors and the evolving role of chemotherapy in BCG-unresponsive disease. The panelists provide insights on emerging data, treatment durability, and practical considerations like patient accessibility and...
TAR-200 Monotherapy for NMIBC Durability and Dwell Time
มุมมอง 6421 วันที่ผ่านมา
TAR-200 Monotherapy for NMIBC Durability and Dwell Time
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
มุมมอง 5921 วันที่ผ่านมา
Treatment Options for BCG-Unresponsive NMIBC: Balancing Efficacy, Logistics, and Patient Preferences
Navigating the BCG Shortage: Gem/Doce and Clinical Trials for NMIBC
มุมมอง 4421 วันที่ผ่านมา
Navigating the BCG Shortage: Gem/Doce and Clinical Trials for NMIBC
Molecular Biomarkers and Risk Stratification in High-Risk Non-Muscle Invasive Bladder Cancer
มุมมอง 5421 วันที่ผ่านมา
Molecular Biomarkers and Risk Stratification in High-Risk Non-Muscle Invasive Bladder Cancer
Upcoming Trials for mHSPC and mCRPC and Next-Generation Sequencing
มุมมอง 4021 วันที่ผ่านมา
Upcoming Trials for mHSPC and mCRPC and Next-Generation Sequencing
Patient Characteristics to Consider for Doublet, Triplet Therapy in mHSPC and mCRPC
มุมมอง 13121 วันที่ผ่านมา
Patient Characteristics to Consider for Doublet, Triplet Therapy in mHSPC and mCRPC
Treatment Considerations After New Data: ARASENS, ARANOTE, and PEACE-3
มุมมอง 6921 วันที่ผ่านมา
Treatment Considerations After New Data: ARASENS, ARANOTE, and PEACE-3
The Growing Field of Radioligand Therapy and Radium Use for mHSPC and mCRPC
มุมมอง 3021 วันที่ผ่านมา
The Growing Field of Radioligand Therapy and Radium Use for mHSPC and mCRPC
Comparing Alpha and Beta Emitters, and Looking to the Future of Advanced Prostate Cancer Care
มุมมอง 5121 วันที่ผ่านมา
Comparing Alpha and Beta Emitters, and Looking to the Future of Advanced Prostate Cancer Care
Biomarkers and Imaging in Upfront Metastatic Prostate Cancer Diagnosis
มุมมอง 7521 วันที่ผ่านมา
Biomarkers and Imaging in Upfront Metastatic Prostate Cancer Diagnosis
Focal Therapy in Prostate Cancer Treatment: An Overview
มุมมอง 5421 วันที่ผ่านมา
Focal Therapy in Prostate Cancer Treatment: An Overview
Navigating Treatment Complexities in First- and Second-Line Therapies for mRCC
มุมมอง 63หลายเดือนก่อน
Navigating Treatment Complexities in First- and Second-Line Therapies for mRCC
The Ideal Patients for TAR-200 and Barriers to Treatment Access
มุมมอง 116หลายเดือนก่อน
The Ideal Patients for TAR-200 and Barriers to Treatment Access
Patient ID, Protocol and Procedure in NMIBC
มุมมอง 71หลายเดือนก่อน
Patient ID, Protocol and Procedure in NMIBC
SunRISe-1 Data: Benefits of the Pretzel Device and Gemcitabine Monotherapy
มุมมอง 118หลายเดือนก่อน
SunRISe-1 Data: Benefits of the Pretzel Device and Gemcitabine Monotherapy
12-month CR of both T-200 and Anktiva +BCG is 58%. 24-month CR of Anktiva is 40%. No data for T-200. For Anktiva, the ongoing response is 47 months and ongoing. It is not only efficiency; duration is also important.
I need a second opinion, can you help me? I have Chromophope kidney cancer.
What is triplet therapy?
I was analyzing your TH-cam channel and you are struggling with subscribers and video views for monetization? Do you want to talk about it for a while?
I was analyzing your TH-cam channel and you are struggling with subscribers and video views for monetization? Do you want to talk about it for a while?
I don’t understand why Cribriform, especially small cell cribriform, would not be treatable with focal therapy. Why.
I have stage 4 metastatic prostate cancer and my psa is jumping up to a doubling point every six months...I feel like I am a lost cause at this point...any suggestions Doctor?
Ibrx
I have visited your TH-cam channel and found out of some problems. Do you want to about it for a while?
🎯 Key points for quick navigation: 00:35 *🏥 The MIRAGE trial compared CT-guided SBRT with MRI-guided SBRT for prostate cancer, aiming to determine patient benefits and reduction in toxicity.* 01:30 *💧 MRI-guided SBRT notably reduced urinary toxicity from 43.4% to 24.4%, showing significant patient benefit.* 01:59 *🍽️ Bowel toxicity was reduced to zero with MRI-guided treatment compared to 10.5% in the CT-guided option.* 02:39 *📉 Patient-reported outcomes showed decreased symptoms in both urinary and bowel areas with MRI guidance.* 02:51 *🎯 MRI guidance significantly reduced patient-reported and physician-scored toxicity in prostate SBRT.* 03:17 *🔧 The MRI-guided linear accelerator allows higher precision, benefiting patient outcomes compared to CT-guided radiation.* 04:24 *🔬 The MIRAGE trial is a strong phase three randomized trial validating the benefits of MRI-guided treatment in the short term.* 04:37 *⏳ Long-term toxicity outcomes are yet to be determined, with two-year and five-year follow-ups planned.* 06:24 *🚀 Future trials aim to leverage MRI's capabilities further for potentially higher dosages to cancer sites, reducing overall toxicity.* 06:42 *🎯 An unexpected robust benefit was found across all metrics, exceeding initial expectations for outcome differences.* 07:38 *⚖️ Plans include assessing the impact on sexual side effects in future studies, potentially favoring MRI-guided treatment.* Made with HARPA AI
I was diagnosed with UTUC (low grade) in May of 2022. I had to have 2 surgeries just to get a biopsy to confirm the diagnosis. (The first one didn’t get enough tissue) Then I had 2 laser surgeries to ablate my tumor(s). My urologist has me come in every 3 months for a cystoscopy, and I will have a CT scan in early December. My care has been only with a urologist. Should I also get an opinion from, and have an oncologist involved? I’m female, 68 years old. Thanks for any info you can give me.
The editing is incorrect. You list the third doctor as Dr Cherington.
2:09,5:50〜7:47
Does anyone have any way to contact Patrick Soon Shiong? Email office, etc????
My husband had robotic prostate removal in October 2023. Gleason score of 5 + 4 following pathology results. PSA began to rise in June to 0.89, then August 5.4 then PSMA pet scan showed two bone lesions, rib and bum bone, PSA rose to 11.5 in September. He has started his hormone therapy and his consultant is recommending a triple therapy from January, combination Darolutamide with Docetaxyl. He is 74, slim and reasonably fit having played sports most of his life. No other medications taken….is this his best chance of prolonging his life?
Is there a Public Access to the Slides used in this presentation - NIAGRA: Study Design; and underlying statistical methodology. Thank you 'good people' of GU Oncology Now
Hi--slides for all the sessions are available to view and download at Uromigos.org.
Now he just needs to stop milking the company and to become profitable
3 month????? I think it's 3 wks.
Congratulations Vishnu!! Very proud of you.
Can we get this in Australia. Clinical trials?
Great discussion!
How significant was the non-recurrence rate increase by adding Anktiva to BCG?
I don’t trust her…
$ibrx to the moon
Grea 2:05 t news .. therapies will be available in Canada in about 20 years😅
It’s funny because immunotherapy is a farce! There has been many purposed reasons and cures for the emperor of all maladies but the FDA goes after the real men and woman who have cured this disease!
This is incredible news! Thanks for sharing this information about PSS and Anktiva.
Wow.
Very helpful. I don’t know if you’re responding to these but I found I had Stage 1A. Tumor less than 4cm (3.7) with RTI but nothing else. I am trying to decide between carboplatin or going surveillance. The way it’s been communicated to me is that I could go from 80% cured to 95%+ cured. I know you can’t say for definite one way or the other but I’d rather not have chemotherapy if I don’t need it but should I have it if I can increase the cure rate?
Same problem now , what did you do ?
Od czasów złowrogiego kowida na dźwięk słowa "ekspert" dostaje odruchu wymiotnego. Ciekawe dlaczego?!
Can Relugolix be combined with Abiraterone?
Si può sapere il punteggio Gleason dei pazienti arruolati nel studio embark? Grazie
P r o m o S M 🙄
Thank you for this video.
Great info. Please do updates.
Would the findings of the MIRAGE random trial still prevail , if BOTH the MRI-guided AND CT-guided radiation were delivered in the LOW-dosage/20-sessions scheme ?? I am about to undergo radiation treatment for Gleason 7 (3+4) with a CT-guided machine in the LOW dosage/20-sessions scheme and wondering if I should postpone it until access to a MRI-guided machine is feasible. Any comments will be much appreciated
Wondering if ever, there will be studies on Ivermectin, Genestein, Apigenin, Curcumin, Oleurpein, IP6 and so forth. (standard is good, Liposomal is better)
I am 54yrs of age, found I have stage 4 rcc in August....have been seeing good results with tkio's....massnated cancer in lungs is gone and tumor shrunk 10%.....
Thanks 👍
You might want to investigate the SeCUre Trial. The results are stunning.
In a nutshell, what did the trial show?
@@wilander1 Am I allowed to answer?
@@wilander1 Can't answer, find my SS
@@DCGreenZone what's your "ss"?
@@wilander1 eeeeee mayle meeeeeee at Geeeeeeeee Mayle
Hi dear, I was impressed by the quality of your videos on your TH-cam channel. The content is top-notch, and the thumbnails are visually appealing. However, I noticed that your SEO could use some improvement. If you optimize your videos for search engines, you'll see a significant increase in viewership. I'd be glad to assist you in this process if you're open to it.
Nice video 😮😮😮
What about SBRT leading to a secondary cancer?
Thanks Dr Deeks !! waited 11 years to hear this. I will investigate futrher ,thank you. Dan dx St4 psa was 72 6 w/ 6mets. 11 years ;later on Zytiga undetectabel for[past 9 years. Gong to City of Hope. now
Thank you for sharing. Concise and informative.
Dr. Kishan said they would be able to announce whether there were any findings about any difference in erectile dysfunction towards the end of 2023, as by then the two year mark will be reached. Are there any findings yet? I am scheduled to do Mridian SBRT in late November, and would love to have good news showing that it will lead to reduced risk of ED before I undergo this treatment.
Was hoping the same. Any updates would be much appreciated.
@@wilander1 Getting ready to start radiation..have the choice of MRI Linac or Proton..sigh..would be nice to have that data now
@@dmcarden After much research, my understanding is that the MRI Linac is the most advanced and targeted technique. Good luck!
Not sure if i am I understanding this panel correctly. I was recently diagnosed with a 53mm RCC and my Urologist wants to perform a Radical Nephrectomy. I am in no pain but only occasional hematuria. If I understand this panel, I should be introduced to immunotherapy for up to 12 weeks and reevaluate then vs running into surgery.
Good stuff
Forced me to watch. Hope it helps. If I make it thru